Linezolid Kabi (Linezolid)

Linezolid Kabi is employed to manage bacterial infections where Gram‑positive pathogens are implicated.

• Skin and soft‑tissue infections: eradicates susceptible Gram‑positive organisms and promotes healing.
• Community‑acquired and nosocomial pneumonia: provides bacteriostatic activity against the causative bacteria.
• Bone and joint infections: penetrates deep tissues to clear complicated Gram‑positive infections.

• Linezolid binds to the 50S ribosomal subunit of susceptible bacteria, preventing formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth, exerting a bacteriostatic effect against Gram‑positive organisms, including resistant strains such as MRSA and VRE.

Linezolid Kabi may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Metallic taste: altered taste perception.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Anemia: reduced hemoglobin levels.
• Peripheral neuropathy: tingling or numbness in extremities.
• Serotonin syndrome: potentially life‑threatening when combined with serotonergic agents.
• Severe liver enzyme elevation: marked increase in hepatic transaminases.
• Hypersensitivity reactions: including anaphylaxis and severe skin eruptions.

When prescribing Linezolid Kabi, clinicians should observe several safety measures.

• Monitor blood counts: watch for thrombocytopenia and anemia.
• Assess renal function: adjust therapy if renal impairment is present.
• Evaluate hepatic status: consider liver function tests before and during treatment.
• Caution with serotonergic drugs: avoid concomitant use with MAO inhibitors or SSRIs.
• Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Linezolid Kabi interacts with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension and serotonin syndrome.
• SSRIs/SNRIs: potential for serotonin syndrome.
• Rifampin: reduces linezolid plasma concentrations.
• Carbamazepine: decreases linezolid exposure.
• Warfarin: may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely)

• NSAIDs: heightened bleeding tendency.
• Ethanol: possible disulfiram‑like reaction.
• Immunosuppressants (e.g., cyclosporine): monitor for altered drug levels.